Abstract This is a renewal application for the Rutgers University CounterACT Research Center of Excellence, which is focused on the discovery and development of drugs to treat poisoning from exposure to vesicants including sulfur mustard, nitrogen mustard, and other mechanistically related chemical threat agents. The Center consists of three Research and Development Projects, each focused on a major vesicant target: the skin, the cornea and the lung. The overall goal of the Center is to identify specific targets in these tissues that can be used for therapeutic intervention. To accomplish this goal, mechanistic research using appropriate models for the skin, cornea and lung is being performed by scientific experts in each of these areas. The Research and Development Projects are supported by a Pharmacology and Drug Development Scientific Support Core and a Pharmaceutics and Medicinal Chemistry Scientific Support Core, each consisting of investigators with considerable expertise in drug discovery, delivery and development. The Rutgers Center has discovered several efficacious lead compounds and developed innovative formulations and delivery systems that increase pharmacological activity and improve pharmacokinetic profiles. Two lead compounds, one for mustard- induced ocular injury and another for mustard-induced lung injury, are FDA approved for other uses, and are being advanced for use as mustard countermeasures. IND-enabling studies have been completed on a lead compound discovered to be effective against mustard-induced skin injury. The Rutgers CounterACT Center has established strategic corporate partnerships for advanced drug development with lead compounds and support by BARDA. A Research Education Core directed at students, postdoctoral trainees, technical staff, and new and established investigators has been highly successful and efforts will be expanded during the next grant period. Plans are to continue mechanistic research with the goal of identifying and developing second generation drug products with improved effectiveness. Current drug leads will also be advanced in the FDA approval process. It is anticipated that Center efforts will result in new drugs that will be in the advanced approval process for treating vesicant poisoning in humans.
|Effective start/end date||9/28/06 → 6/30/20|
- Pharmaceutical Science
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.